What the FDA labels say about taking them together
Erlotinib and rifapentine
Erlotinib's FDA label of June 10, 2024 names rifapentine in its drug interactions section; the rifapentine label PlainMeds reads does not name erlotinib. The erlotinib label: “Increase the erlotinib dosage if co-administration with CYP3A4 inducers is unavoidable.”
Check it at the source: the erlotinib FDA label on DailyMed (effective June 10, 2024, Alembic Pharmaceuticals Limited); the rifapentine FDA label on DailyMed (effective February 6, 2026, sanofi-aventis U.S. LLC).
What does the erlotinib label say about rifapentine?
Erlotinib label, drug interactionsIncrease the erlotinib dosage if co-administration with CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, rifabutin, rifapentine, phenobarbital and St. John's wort) is unavoidable [see Dosage and Administration (2.4)].
Source: FDA drug label (ERLOTINIB HYDROCHLORIDE), Alembic Pharmaceuticals Limited, effective June 10, 2024 (SPL set ab6f3cb3-34a8-4492-a5d7-fb6b055a2d6b), via openFDA; the full label on DailyMed
What does the rifapentine label say about erlotinib?
Rifapentine's label (effective February 6, 2026) does not name erlotinib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Priftin), sanofi-aventis U.S. LLC, effective February 6, 2026 (SPL set 3a64fb70-b85e-43d9-8bcd-7e893f568ae1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Erlotinib | Rifapentine | |
|---|---|---|
| Labeled for | Lung cancer | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $4.83 per tablet 150 mg tablet |
| Shortage now | No current entry | Resolved |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once